Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
Artiva Biotherapeutics, Inc. (ARTV)
Company Research
Source: GlobeNewswire
The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy, highlighting a favorable tolerability profile observed to date and the feasibility of patient management in outpatient rheumatology clinics Initial translational data highlighting uniform, consistent, deep B-cell depletion supporting AlloNK’s intended mechanism of action SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will host a virtual event discussing initial safety and translational data for AlloNK® in combination with anti-CD20 antibodies across autoimmune diseases. The webcast will feature: Initial safety data for 32 patients with au
Show less
Read more
Impact Snapshot
Event Time:
ARTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTV alerts
High impacting Artiva Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ARTV
News
- Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.MarketBeat
- Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Artiva Biotherapeutics GAAP EPS of -$0.88 [Seeking Alpha]Seeking Alpha
- Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease [Yahoo! Finance]Yahoo! Finance
- Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune DiseaseGlobeNewswire
ARTV
Sec Filings
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- ARTV's page on the SEC website